quinoxalines has been researched along with Kahler Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, CM; Edwards, JR; Gooding, S; Javaid, MK; Leung, SK; Lwin, ST; Nador, G; Olechnowicz, SWZ; Ramasamy, K; Rao, SR; Weivoda, MM | 1 |
| Ichijo, T; Joshita, S; Kawakami, F; Kobayashi, H; Nakazawa, H; Sugiura, A; Umemura, T; Wakabayashi, SI; Yamashita, Y; Yamazaki, T | 1 |
| Alcolea, V; Amin, S; Karelia, DN; Palop, JA; Pandey, MK; Plano, D; Sanmartín, C; Sharma, AK; Singh, P | 1 |
| Ahn, J; Alley, KM; Bachovchin, KA; Fazzini, A; Gauntner, TD; Gilchrist, A; Ha, SJ; Mazzoni, MR; Merritt, JR; Pyen, DS; Sansom, SE; Willett, A; Yarfi, JL | 1 |
| Alsina, M; Beg, AA; Boulware, D; Chen, DT; Dalton, WS; Hazlehurst, LA; Mathews, L; Oliveira, V; Shain, KH; Villagra, A; Wang, X; Yarde, DN | 1 |
| Garrison, J; Macdonald, JS; Marshall, ME | 1 |
1 review(s) available for quinoxalines and Kahler Disease
| Article | Year |
|---|---|
Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature.
Topics: Aged; Aminoisobutyric Acids; Antibodies, Monoclonal; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Multiple Myeloma; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
5 other study(ies) available for quinoxalines and Kahler Disease
| Article | Year |
|---|---|
Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.
Topics: Adiponectin; Animals; Bone Marrow; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Multiple Myeloma; Nerve Growth Factor; Neuroglia; NF-kappa B; Osteoblasts; Pain; Peptides; Piperidines; Quinoxalines; Stromal Cells; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2019 |
Identification of a Novel Quinoxaline-Isoselenourea Targeting the STAT3 Pathway as a Potential Melanoma Therapeutic.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Humans; Molecular Docking Simulation; Multiple Myeloma; Mutation; Organoselenium Compounds; Phosphorylation; Protein Conformation; Proto-Oncogene Proteins B-raf; Quinoxalines; Signal Transduction; STAT3 Transcription Factor | 2019 |
Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
Topics: Animals; Arrestins; beta-Arrestins; Cell Line, Tumor; Chemokine CCL3; Chemotaxis; CHO Cells; Cricetulus; HEK293 Cells; Humans; Multiple Myeloma; Phenylurea Compounds; Piperidines; Quinoxalines; Radioligand Assay; Receptors, CCR1; Spiro Compounds | 2014 |
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Gene Expression; Humans; Imidazoles; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Quinoxalines; Transcription Factor RelB | 2009 |
Unusual skin reaction to echinomycin.
Topics: Echinomycin; Humans; Male; Middle Aged; Multiple Myeloma; Quinoxalines; Skin Ulcer | 1987 |